On the Horizon – Sunitinib Malate for Metastatic Castration-Resistant Prostate Cancer Following Docetaxel Chemotherapy

Docetaxel (Taxotere), or chemotherapy, will as all other treatments for advanced prostate cancer stop working. Many of us will progress quickly to this stage and eventually face a situation where there are no longer any approved treatments available to control our prostate cancer. If you are lucky enough to have an oncologist who is creative [...]

Chemo Brain – Yes, Prostate Cancer Survivors Do Suffer From It

Today’s New York Times has published another of its fantastic articles about cancer and coping with cancer. Today’s article, written by Jane Brody, discusses chemo brain. Until a short time ago, many doctors denied that it even existed, but today it is pretty much accepted as being real. One is said to suffer from chemo [...]

CB7630 (Abiraterone Acetate) to Enter Phase III Trial

There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]

Living My Life In Three Week Cycles

Scott Goodwin has been a guest writer on this blog. He has been sharing his experiences and feelings as he continues his journey on chemotherapy. Scott is not doing as well as we all had hoped. His final paragraph says "When does the time come when a man will stop all treatments and try to [...]

Toxicity and Efficacy of Intermittent Docetaxel Chemotherapy for Hormone Refractory Prostate Cancer

Once we become hormone refractory (HRPC) there remains only one approved drug to treat our prostate cancer, docetaxel. As with hormone therapy (ADT) docetaxel also stops working after a period. There have been different strategies used to try to deal with this untenable situation, including the use of docetaxel on an intermittent schedule. A recent [...]

Go to Top